Cantor Still Expects Threshold Pharma To More Than Triple, Says 2016 Will Be 'Data Rich' Year
July 02, 2015 at 09:09 AM EDT
In a report published Thursday, Cantor Fitzgerald analyst Daniel Brims maintained a Buy rating and $14 price target on Threshold ...
